Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease

Completed · Not applicable

Conditions studied: Chronic Kidney Disease

In brief

This study is to research two questions. First, is vitamin D3 more effective than vitamin D2 in raising 25-hydroxyvitamin D \[25(OH)D\] levels in chronic kidney disease (CKD) patients? And secondly, what are the differential effects of vitamin D2 and vitamin D3 on other mineral metabolism parameters?

Key facts

Study ID

NCT01835691

Run by

University of Kansas Medical Center

People needed

44

Starts

2011-10-01

Expected to finish

2015-06-01

Last updated by the study team

2017-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 and above
• Chronic kidney disease with an estimated glomerular filtration rate (GFR) between 15-60 ml/min (CKD stage III-IV)
• Vitamin D insufficiency (25-hydroxyvitamin D level < 30 ng/mL) that has not been treated with vitamin D replacement since the acquisition of this level

You may not qualify if…

• Current treatment with cholestyramine
• Presence of GI disorders such as short bowel, history of gastrectomy, colectomy, gastric bypass, inflammatory bowel disease, celiac disease, disorders of fat absorption, chronic diarrhea.
• Liver cirrhosis
• Known current substance abuse
• Current treatment with immunosuppressant medications
• Presence of chronic infection
• History of chronic inflammatory disease (i.e. - lupus, active rheumatoid arthritis, Crohns disease)
• Currently receiving high-dose vitamin D replacement (avg dose of ≥ 3,000 U per day) or "active" vitamin D analogue (e.g., calcitriol, which is 1,25-dihydroxyvitamin vitamin D).

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.